<DOC>
	<DOCNO>NCT01982396</DOCNO>
	<brief_summary>Cross-over 28 week study plasma pharmacokinetic profile twice daily 3TC ( 4mg/kg/dose BD ) daily 3TC ( 8mg/kg/dose OD ) twice daily ABC ( 8mg/kg/dose BD ) daily ABC ( 16mg/kg/dose OD ) one drug take part combination antiretroviral therapy .</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) Study Twice Daily vs Once Daily Lamivudine ( 3TC ) Abacavir ( ABC ) Part Combination Antiretroviral Therapy ( ART ) HIV Infected Children</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Children definitive HIV infection Age &gt; 2 &lt; 13 year Currently combination ART include 3TC / ABC , least 6 month , stable CD4 cell count HIV RNA viral load expect stay regimen least 3 month . â€¢ Intercurrent illness Receiving concomitant therapy except prophylaxis Pneumocystis carinii pneumonia ( PCP ) Abnormal renal liver function ( grade 3 )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>paediatric</keyword>
	<keyword>Abacavir</keyword>
	<keyword>lamivudine</keyword>
</DOC>